Literature DB >> 1260698

Malignant ovarian tumors in childhood: prognosis in relation to initial therapy.

N Wollner, P R Exelby, J M Woodruff, W C Cham, M L Murphy, J L Lewis.   

Abstract

Twenty-two children with malignant ovarian tumors (12 malignant teratomas, six endodermal sinus tumors, and four embryonal carcinomas) were studied from 1960 through March 1975. Comparison is made between different modalities of therapy, such as surgery alone or surgery in combination with either radiation or chemotherapy. Because of the poor results obtained with the aforementioned treatment methods, a new approach, consisting of more aggressive initial surgery followed immediately by radiation therapy and an intensive chemotherapeutic regimen called the T2 protocol, was begun in 1971 with encouraging results. To date six of ten patients are alive and free of disease with a median observation period of 22+ months. A new grouping defining the extent of disease is also provided. Of the ten patients on the T2 protocol, only one was a Group I; eight were Group III and one was Group IV at the time treatment was initiated. An analysis of the mode of spread, as well as a discussion of the results obtained with previous modalities of therapy in relation to initial grouping and pathology, constitute the background for the proposed treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260698     DOI: 10.1002/1097-0142(197604)37:4<1953::aid-cncr2820370447>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Malignant teratomas in infancy and childhood.

Authors:  M M Woolley
Journal:  World J Surg       Date:  1980-01       Impact factor: 3.352

2.  Combination chemotherapy in malignant non-seminomatous germ-cell tumors: results of a cooperative study of the German Society of Pediatric Oncology (MAKEI 83).

Authors:  U Gobel; G Calaminus; R J Häas; H Jurgens; D Niethammer; J Ritter; H J Spaar; D Harms
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.